NeuroMetrix Reports Strong Quell Demand in Q4 2016

Invoiced Value of Quell Shipments Up 19% Over Q3 2016

January 10, 2017 07:00 AM Eastern Daylight Time

WALTHAM, Mass.--(EON: Enhanced Online News)--NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO, NUROW) reported Q4 2016
demand highlights for its Quell® Wearable Pain Relief
Technology™. During Q4 2016 the invoiced value of Quell shipments
totaled approximately $3.5 million, an increase of 19% from $2.9 million
reported in Q3 2016. This was the 7th consecutive quarter of
sequential growth since commercial launch in 2015. The Quell invoiced
value in Q4 2016 reflects shipments of approximately 14,300 devices and
20,000 reorder electrodes, a growth rate of 18% in devices and 39% in
electrodes from Q3 2016. To date, the Company has shipped nearly 60,000
devices.

Today at 11:30 am (Pacific Time), Shai N. Gozani M.D., Ph.D., President
and Chief Executive Officer, will discuss Quell and the Company's
business activities at the 9th annual Biotech Showcase
Conference at the Hilton San Francisco Union Square. A live audio
webcast will be available on the investor relations section of the
corporate website - www.neurometrix.com.

The Company intends to report its financial results for the fourth
quarter and full year 2016 on January 26, 2017.

About Quell

Quell is designed for millions of people suffering from chronic pain.
The advanced wearable device is lightweight and can be worn during the
day while active, and at night while sleeping. It has been cleared by
the FDA for treatment of chronic pain without a prescription. In a
recent study, 81% of Quell users reported an improvement in their
chronic pain. Quell users can personalize and manage therapy discreetly
via the Quell Relief app. Quell also offers advanced health tracking
relevant to chronic pain sufferers including pain, sleep, activity, and
gait. Quell was the winner of the 2016 SXSW (South by Southwest)
Innovation Award for Best Wearable Technology. Quell is available at
select healthcare professionals and retailers. Visit QuellRelief.com for
more information.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company
combining bioelectrical and digital medicine to address chronic health
conditions including chronic pain, sleep disorders, and diabetes. The
company's lead product is Quell, an over-the-counter wearable
therapeutic device for chronic pain. Quell is integrated into a digital
health platform that helps patients optimize their therapy and decrease
the impact of chronic pain on their quality of life. The company also
markets DPNCheck®, a rapid point-of-care test for diabetic
neuropathy, which is the most common long-term complication of Type 2
diabetes. The company maintains an active research effort and has
several pipeline programs, including a therapeutic device for restless
leg syndrome. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit www.NeuroMetrix.com.